Akcea Therapeutics, Inc., a subsidiary of Ionis Pharmaceuticals, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2015, Akcea focuses on developing and commercialising innovative therapies for patients with serious and rare diseases, particularly those related to lipid disorders and neurological conditions. The company’s core products, including TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), are designed to address unmet medical needs, showcasing unique mechanisms of action that set them apart in the market. With a commitment to advancing patient care, Akcea has established a strong market position, recognised for its contributions to the field of RNA-targeted therapeutics. Through strategic partnerships and a robust pipeline, Akcea Therapeutics continues to make significant strides in the biopharmaceutical industry.
We don't have data for Akcea Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company